CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 192 enrolled
Drug / intervention
Botulift +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01180348
NCT01180348Phase 3Completed
CompareCT.gov

Randomized Study of Clinical Non-inferiority of Medicine Botulift (Laboratório Químico Farmacêutico Bergamo Ltd.) Compared to Botox ® (Allergan Inc.) in the Improvement of Wrinkles in the Facial Region.

Azidus Brasil·interventional·Posted Aug 12, 2010·Updated Mar 4, 2016

In Brief

A Phase 3 clinical trial evaluating Botulift and Botox for Wrinkles. Completed, enrolled 192 participants across 1 site.

Detailed Summary

The dermatological treatment for reducing facial wrinkles with injectable drug Botulift (botulinum toxin type A - Laboratório Químico Farmacêutico BergamoLtd.) has a not inferior activity when compared with Botox ® (botulinum toxin - Allergan Inc.) in clinical trials.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWrinkles
CountriesBrazil
CollaboratorsLaboratório Químico Farmacêutico Bergamo Ltda.

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 12, 2010
Enrollment StartAug 1, 2011
Primary CompletionOct 1, 2011
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.9 years ago

Interventions

Botuliftdrug

Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).

Botoxdrug

Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).